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Simple Summary: Metastasis is one of the most devastating aspect of cancer progression and involves
biochemical and physical interactions between cancer cells and surrounding microenvironment. In
particular, cancer cells adhesion to endothelium and their subsequent transendothelial migration
represent important steps in the metastatic process in target organs. In this study we characterized
the functional role of Protein Disulfide Isomerase A1 (PDIA1) in breast cancer cells adhesion
and transendothelial migration. We identified the full repertoire of protein disulfide isomerases
in endothelial cells as well as in breast cancer cells. We provided insight into the mechanisms
involved in cancer-endothelial cells interactions and suggested that PDIA1 regulates the adhesion
and transendothelial migration of breast cancer cells by disulphide exchange involving most likely
the activation of integrins. Our results suggest that the inhibition of extracellular PDIA1 or other
PDIs represents an interesting target for anti-metastatic treatment.
Abstract: Cancer cell cross-talk with the host endothelium plays a crucial role in metastasis, but
the underlying mechanisms are still not fully understood. We studied the involvement of protein
disulphide isomerase A1 (PDIA1) in human breast cancer cell (MCF-7 and MDA-MB-231) adhesion
and transendothelial migration. For comparison, the role of PDIA1 in proliferation, migration, cell
cycle and apoptosis was also assessed. Pharmacological inhibitor, bepristat 2a and PDIA1 silencing
were used to inhibit PDIA1. Inhibition of PDIA1 by bepristat 2a markedly decreased the adhesion
of breast cancer cells to collagen type I, fibronectin and human lung microvascular endothelial
cells. Transendothelial migration of breast cancer cells across the endothelial monolayer was also
inhibited by bepristat 2a, an effect not associated with changes in ICAM-1 expression or changes
in cellular bioenergetics. The silencing of PDIA1 produced less pronounced anti-adhesive effects.
However, inhibiting extracellular free thiols by non-penetrating blocker p-chloromercuribenzene
sulphonate substantially inhibited adhesion. Using a proteomic approach, we identified that β1
and α2 integrins were the most abundant among all integrins in breast cancer cells as well as in
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lung microvascular endothelial cells, suggesting that integrins could represent a target for PDIA1.
In conclusion, extracellular PDIA1 plays a major role in regulating the adhesion of cancer cells and
their transendothelial migration, in addition to regulating cell cycle and caspase 3/7 activation by
intracellular PDIA1. PDIA1-dependent regulation of cancer–endothelial cell interactions involves
disulphide exchange and most likely integrin activation but is not mediated by the regulation of
ICAM-1 expression or changes in cellular bioenergetics in breast cancer or endothelial cells.
Keywords: protein disulphide isomerase A1; adhesion; transendothelial migration; disulphide exchange
1. Introduction
Cancer cell metastasis, the major cause of cancer patient death [1], is a complex phenomenon.
It involves cancer cell invasion at the primary site, survival and arrest in the bloodstream, and
finally, extravasation at a distant site. Cancer cell adhesion and the subsequent transmigration across
endothelium to distant organs is a crucial step of metastasis. Organ-specific colonisation is a key
feature of most metastatic cancer cells, and breast cancer cells tend to infiltrate the bone, brain, liver
and lungs [2–5]. Despite the extensive literature, the mechanisms that promote the adhesion of breast
cancer cells to organ-specific endothelial layers remain unclear. Better understanding of the specific
molecular mechanisms used by cancer cells to activate dynamic interactions with endothelial cells is
instrumental to identify promising novel molecular targets for anti-metastatic therapy.
Interestingly, protein disulphide isomerases (PDIs), a group of enzymes exhibiting oxidoreductase
activity, have been recently demonstrated to be involved in the modulation of adhesive inter-cellular
interactions with endothelium [6,7]. Cell-surface or secreted PDIs regulate platelet adhesion and
thrombosis [8–10] as well as leukocyte adhesion to endothelium [7]. PDIs are now known to reside
not only in the endoplasmic reticulum (ER), regulating protein folding by forming, breaking and
rearranging disulphide bonds [11]; various PDIs have been detected in other cellular locations,
including the surface of platelets, leukocytes, endothelial cells and cancer cells, and they regulate
various protein functions by modifying extracellular disulphide bonds [6,11–16].
Recent studies have shown that several PDIs, such as PDIA1, PDIA3 and PDIA6, are upregulated
in different cancer types, including kidney, lung, brain, ovarian, melanoma, prostate and male germ-cell
tumours, and over-expression of PDIs may serve as a diagnostic marker for cancer [11,15,17,18]. In
particular, prolyl 4-hydroxylase, β polypeptide (P4HB), also known as PDIA1, is upregulated in
numerous types of cancer [19–23], and its over-expression is associated with advanced-stage tumours
and poor prognosis. These findings have been explained by showing that PDIA1 was involved
in regulating cancer cell malignancy [24], apoptosis [25] and proliferation [10]. However, it is not
known whether PDIA1 regulates cancer cell interactions with endothelium, such as adhesion and
transmigration, key processes involved in cancer metastasis.
In the present study, we aimed to fill this gap and identify the relative importance of PDIA1 in
regulating interactions of human breast cancer cells (MCF-7 and MDA-MB-231) with lung microvascular
endothelial cells. For comparison, we evaluated the role of PDIA1 in proliferation, migration and
regulation of the cell cycle, apoptosis and cancer growth in colony formation assays. We identified
PDIA1 as a major isoform of PDIs present in human breast cancer cells and lung microvascular
endothelial cells and studied the effects of PDIA1 inhibitor, bepristat 2a and PDIA1 silencing on
cancer–endothelium interactions and other functional aspects of the cancer cell phenotype. We also
explored whether the effects of PDIA1 inhibition on cancer–endothelial cell interactions could be
attributed to disulphide re-arrangement of integrins known to mediate adhesion of platelets and
leukocytes to endothelium [7,26–28], to cellular bioenergetics in breast cancer or endothelial cells, an
important target for anti-adhesive mechanisms [29], or to alterations in ICAM-1 expression involved in
this interaction [30].
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2. Results
2.1. Relative Content of PDIA1 in Comparison to Other Isoforms of PDIs in MDA-MB-231, MCF-7 and
hLMVEC Cell Lines
As shown in Table 1, PDIA1 was the most abundant isoform of all PDIs in all three cell types.
PDIA3, PDIA4 and PDIA6 content was also relatively high, but lower compared with PDIA1. Other
PDI isoforms were expressed at much lower levels. Interestingly, PDIA17 was present in MCF-7 cells
at relatively high levels, while in MDA-MB-231, the expression of PDIA17 was low and not detectable
in hLMVECs.
Table 1. Relative content of protein disulphide isomerases (PDIs) in hLMVEC, MCF-7 and MDA-MB-231
cell lines.
PDI Isoform hLMVEC [Mean ± SD] MCF-7 [Mean ± SD] MDA-MB-231 [Mean ± SD]
PDIA1 10.297 ± 1.374 8.987 ± 2.895 7.220 ± 0.907
PDIA3 7.313 ± 0.918 7.920 ± 4.092 5.063 ± 0.903
PDIA4 4.020 ± 0.000 4.387 ± 2.620 2. 943 ± 1.101
PDIA5 0.233 ± 0.085 0.235 ± 0.120 not detected
PDIA6 3.503 ± 0.231 2.807 ± 0.512 1.833 ± 0.006
PDIA9 2.160 ± 0.000 2.630 ± 1.250 2.190 ± 0.460
PDIA10 0.660 ± 0.087 1.380 ± 0.314 0.663 ± 0.179
PDIA11 0.420 ± 0.104 0.850 ± 0.678 0.567 ± 0.319
PDIA12 0.130 ± 0.104 0.130 ± 0.000 0.130 ± 0.000
PDIA13 0.177 ± 0.095 not detected 0.130 ± 0.071
PDIA14 0.110 ± 0.000 0.240 ± 0.000 not detected
PDIA15 3.443 ± 1.564 1.670 ± 0.962 1.783 ± 0.365
PDIA16 1.217 ± 0.266 0.440 ± 0.173 0.540 ± 0.000
PDIA17 not detected 6.117 ± 1.58 0.230 ± 0.000
PDIA18 not detected 1.640 ± 0.896 not detected
PDIA19 0.380 ± 0.104 0.260 ± 0.000 0.100 ± 0.000
Semi-quantitative data (emPAI) for each detected PDI isoform in lysates from human lung microvascular endothelial
cells (hLMVEC) and breast cancer MCF-7 and MDA-MB-231 cell lines. Data represent the means ± SD from three
consecutive passages. emPAI was calculated based on the number of observed peptides per proteins normalized by
the theoretical number of peptides subtracted from LC-MS/MS data using MascotTM (Matrix Sciences, London, UK).
2.2. Silencing of PDIA1 in MDA-MB-231 and MCF-7 Cell Lines
To inhibit the function of PDIA1 in breast cancer cell lines, sublines with silenced PDIA1 were
constructed. The efficacy of the silencing procedure was confirmed by real-time PCR and Western
blot. Based on these results, two sublines were selected for further studies (Figure S1, uncropped
western blot figures are shown in Figure S8). The silencing of PDIA1 did not affect MDA-MB-231
cell proliferation but significantly decreased MCF-7/shPDIA1-1 cell proliferation compared to shN
(Figure S1). To further confirm PDI content after PDIA1 silencing in selected two sublines showing
>70% inhibition by real-time PCR and Western blot, proteomic analysis of these transduced cell lines
was performed. Table 2 shows that the silencing of PDIA1 in MCF-7 cells was more pronounced using
shPDIA1-1 hairpin (>95% downregulation), while shPDIA1-3 had a weaker effect but also proved
effective (ca 80% downregulation). In MDA-MB-231, effective silencing of PDIA1 was achieved using
shPDIA1-3 hairpin only (ca 80% downregulation), but a reduction in PDIA1 was also noted in the shN
group, and in MDA-MB-231/shPDIA1-1, subline expression of PDIA1 was upregulated compared to
shN. Importantly, in PDIA1-silenced cells, other PDIs were neither upregulated nor downregulated.
Cancers 2020, 12, 2850 4 of 22
Table 2. Relative content of PDIs (emPAI) in MCF-7 and MDA-MB-231 cell lines after PDIA1 silencing.
PDI
Isoform
MCF-7 Cells MDA-MB-231 Cells
Wild
Type shN shPDIA1-1 shPDIA1-3
Wild

















































































































































































































































Semi-quantitative data for each detected PDI isoform (emPAI) in lysates from breast cancer MCF-7 and MDA-MB-231
cell lines after PDIA1 silencing. Data represent the means ± SD from minimum of 3 consecutive passages
(MCF-7, WT—n = 5, shN—n = 4, shPDIA1-1—n = 4, shPDIA1-3—n = 3; MDA-MB-231, WT—n = 5, shN—n = 4,
shPDIA1-1—n = 5, shPDIA1-3—n = 4). emPAI was calculated based on the number of observed peptides per
proteins normalized by the theoretical number of peptides subtracted from LC-MS/MS data using MascotTM (Matrix
Sciences, London, UK).
2.3. Inhibition of PDIA1 by Bepristat 2a
To show that bepristat 2a selectively targets PDIA1, insulin reduction assay was used. As shown in
Table 3, bepristat 2a selectively inhibited the reductive activity of PDIA1. Bepristat 2a was characterized
by much lower IC50 for PDIA1 as compared with PDIA3 (2.1 µM for PDIA1, 127 µM for PDIA3). In
addition, bepristat 2a did not affect the reductive activity of other PDI isoforms tested, such as PDIA4,
PDIA6 and PDIA17.
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Table 3. Insulin reduction by PDIA1, PDIA3, PDIA4, PDIA6 and PDIA17 in the presence of bepristat 2a.
Bepristat 2a [µM]
Enzymatic Activity, % of Initial
PDIA1 PDIA3 PDIA4 PDIA6 PDIA17
200 20 ± 6 36 ± 5 80 ± 2 69 ± 4 46 ± 8
20 42 ± 2 86 ± 4 89 ± 3 99 ± 2 95 ± 3
2 63 ± 2 103 ± 4 102 ± 2 95 ± 3 98 ± 3
0.2 72 ± 3 105 ± 2 100 ± 2 103 ± 2 100 ± 2
0.02 90 ± 3 not detected not detected not detected not detected
IC50 2.1 127 >200 >200 ≥200
Recombinant PDIA1, PDIA3, PDIA4, PDIA6 and PDIA17 enzymes were incubated with bepristat 2a at various
concentrations (0.02–200 µM) for 60 min at 37 ◦C, and then the activity of enzymes was monitored in insulin
turbidimetric assay. Data represent the means ± SD obtained from 3 independent experiments. Effects of bepristat
2a inhibition on PDI isoforms are expressed as IC50 values.
2.4. Effect of PDIA1 Inhibition on Cell Proliferation
To determine the cellular response to PDIA1 inhibition, several functional assays evaluated cancer
cell phenotype. First, to ensure that the observed effects of bepristat 2a on cancer cell adhesion and
transendothelial migration were not related to the cytotoxic activity of this compound, a cell viability
assay was performed. As illustrated in Figure S2, bepristat 2a applied at concentrations 1–50 µM for 24
h did not affect MCF-7 or MDA-MB-231 cell viability. A decrease in the viability of all tested cell lines
was observed after 100 µM of bepristat 2a. However, bepristat 2a applied at a concentration of 50 µM
for 48 h influenced MCF-7 and MDA-MB-231 cell viability. To exclude the observed effects of bepristat
2a on cancer cell adhesion, migration and transendothelial migration, being related to the cytotoxic
activity of this compound, further experiments were performed using bepristat 2a at a concentration
range of 1–50 µM. Next, the effect of PDIA1 inhibition on caspase 3/7 activity in breast cancer cells
was explored. In neither MCF-7 nor MDA-MB-231 cell lines did PDIA1 silencing affect the activity
of caspase 3/7 (Figure S3). However, in both cell lines, bepristat 2a used at a concentration of 50 µM
significantly activated caspase 3/7 (increase of over 20× in MCF-7 and 10× in MDA-MB-231 compared
to untreated control after 48 h and similarly after 24 h of incubation). A statistically significant
increase in caspase 3/7 activity was also observed at a concentration of 30 µM of bepristat 2a (over 3×
increased activity in both MCF-7 and MDA-MB-231 compared to untreated control after 24 and 48 h
incubation; Supplementary Figure S3). Finally, the cell cycle distribution of breast cancer cells after
PDIA1 inhibition was examined. The most visible changes in the cell cycle of MCF-7 and MDA-MB-231
cells were observed in S phase, 24 and 48 h after bepristat 2a application (Figure S4). These changes
were accompanied by reciprocal changes in the sub-G1, G0/G1 and G2/M phases, which became more
apparent after 48 than 24 h. We also analysed the cell cycle of transduced MCF-7 and MDA-MB-231
cells. The cell cycle of MCF-7 and MDA-MB-231 with silenced PDIA1 was less disrupted compared to
the action of bepristat 2a. Similarly to the effects of bepristat 2a, the silencing of PDIA1 resulted in a
lower percentage of MCF-7/shPDIA1-1 cells (where the inhibition of PDIA1 was greater than 95%)
in the G2/M phase, while the changes in the sub-G1, G0/G1 and S phases were less marked. After
the silencing of PDIA1 in MDA-MB-231 cells, we found no changes in the G0/G1, S or G2/M phases
(Figure S5).
2.5. Effect of PDIA1 Inhibition on Clonogenic Capacity of Breast Cancer Cells
MCF-7 and MDA-MB-231 cells pre-treated with bepristat 2a presented a significantly lowered
ability to form colonies. This inhibitory activity of bepristat 2a was stronger against MDA-MB-231
than MCF-7 cells (Figure 1A,B). However, the silencing of PDIA1 in MCF-7 or MDA-MB-231 cells
did not downregulate the clonogenicity of these cells. Furthermore, the transduction procedure itself
diminished the clonogenicity of MCF-7/shN and MDA-MB-231/shN cells (Figure 1C,D).
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(D) cells transduced with lentiviral vectors carrying short hairpin RNA (shRNA) against PDIA1 or
negative s quence after selection with puromycin in regarding to wild type cell line. Data rep sent the
m ans ± SD with po nts f r individual measure ents, the representativ photos are als presented.
Statistical analysis was calculated u ing par metric one-way ANOVA followed by Dunnett’s multiple
comparisons test (* p = 0.05, ** p = 0.01, *** p = 0.001, **** p = 0.0001).
2.6. Effects of PDIA1 Inhibition on Wound Healing and Migration of Breast Cancer Cells and Endothelial Cells
In the Electric Cell-Substrate Impedance Sensing (ECIS)-based wounding assay for breast cancer
cells and endothelial cells, the resistance of hLMVEC, MCF-7 and MDA-MB-231 cells untreated and
after exposure to bepristat 2a (1–30 µM; Figure 2A,C,E) recovered rapidly to the state observed before
electrical wounding. In hLMVECs, bepristat 2a at a 50 µM concentration induced a transient decrease
in migration rate. After the incubation of MDA-MB-231 cancer cells with 50 µM of bepristat 2a, the
recovery was less rapid than in the case of other concentrations, while MCF-7 cells migrated to the
level observed before wounding similarly to control groups. Indeed, AUC for wound-healing response
for hLMVEC and MDA-MB-231 but not for MCF-7 cells treated by bepristat 2a at 50 µM concentration
was lower as compared to non-treated respective control cells (Figure 2B,D,F). Although the silencing
of PDIA1 in MDA-MB-231 cells also induced changes in migration rate, this might be attributed to
transduction effects. These results quantified by calculating the AUC wound-healing response for
MCF-7 and MDA-MB-231 sublines (shPDIA1-1, shPDIA1-3) versus negative control (shN) are shown
in Figure 2G–J.
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Figure 2. Effects of PDIA1 inhibition on ound-healing and migration of breast cancer cells and
endothelial cells. ECIS Wound-Healing ssa of , CF-7 and MDA-MB-231 cells and breast
cancer sublines with silencing of PDIA1 (sh , I - d shPDIA1-3). Real time tracings in
hLMVECs (A), MCF-7 (C) and MD - ll lines after a d tion of bepris at 2 at various
concentrations (1, 10, 0 µM) and after PDIA1 sile ci g in MCF-7 (G) and DA-MB-231 (I)
ce l lines. Area under the curve boxplots present AUC qu ntitation of changes n migration rate
of ristat 2a-treated hLMVECs (B), MCF-7 (D) and MDA-MB-231 (F) ce l lines ver us on-treated
controls as well as MCF-7 (H) or MD - - (J) lines transduced against PDIA1 (shPDIA1-1,
shPDIA1-3) or wild type cells regarding to negative sequence (shN). The line graphs and AUC boxplots
represent mean ± SD of three independent experiments. Statistical analysis was calculated using
parametric one-way ANOVA followed by Dunnett’s multiple comparisons test (* p = 0.05, ** p = 0.01,
*** p = 0.001).
2.7. Effect of PDIA1 Inhibition on Adhesio f l to the Endothelium
As shown in Figure 3, t i i ition of PDIA1 by bepristat 2a resulted in decreased adhesion
of both CF-7 (Figure 3A) and MDA-MB-231 cells (Figure 3B) to endothelial monolayers in a
concentration-dependent manner. Next, e exa ined the adhesion of MCF-7 and MDA-MB-231 cells
after transduction with lentiviral vectors carrying shRNA against PDIA1. As shown in Figure 3, the
downregulation of PDIA1 had no effect on MCF-7/shPDIA1-1 or MCF-7/shPDIA1-3 cell adhesion to
hLMVECs compared to MCF-7/shN (Figure 3C). In the case of transduced MDA-MB-231 cells,
MDA-MB-231/shN cells adhered much more weakly to the hLMVEC monolayer than did the
MDA-MB-231 wild type, an effect interfering with the results of silencing in MDA-MB-231/shPDIA1-1
and MDA-MB-231/shPDIA1-3 (Figure 3D).
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Figure 3. Effect of PDIA1 inhibition on adhesion of breast cancer cells to the endothelium, collagen type
I and fibronectin and their transendothelial migration across hLMVEC monolayer. Effect of bepristat 2a
on adhesion of MCF-7 (A,E) and MD -MB-231 (B,F) cells to hLMVEC, collagen type I and fibronectin,
respectively, and MCF-7 (C,G) and MDA-MB-231 (D,H) cells transduced with lentiviral vectors carrying
short hairpin RNA (shRNA) against PDIA1 or negative sequence after selection with puromycin in
regardi g to wild type cell line. Tra sendothelial migration of MCF-7 (I) and MDA-MB-231 (J) cells
treated with bepristat 2a and MCF-7 (K) and MDA-MB-231 (L) sublines with silenced PDIA1 expression
acros hLMVEC monolayer . Dat represent mean ± SD of th ee independ nt experiments. Statistical
analysis was perfor d using one-way ANOVA followed by Dun ett’s multiple comparisons test or
no parametric Kruskal–Wallis followed by Dunn’s multiple compar ons test (* p = 0.05, ** p = 0.01,
*** p = 0.001, **** p = 0. 0 1).
2.8. Effects of PDIA1 Inhibition on Adhesion of Cancer Cells to Fibronectin and Collagen Type I
The adhesion of MCF-7 and MDA-MD-231 cells to both ECM proteins was significantly inhibited
by bepristat 2a used at a concentration of 50µM, while 30µM effectively inhibited the adhesion of MCF-7
cells to collagen and MDA-MB-231 cells to fibronectin (Figure 3E,F). In contrast to pharmacological
blockade, the silencing of PDIA1 did not affect the adhesion of either cell line to either ECM protein
(Figure 3G,H).
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2.9. Effect of PDIA1 Inhibition on Transmigration of Cancer Cells across the Endothelium
As shown in Figure 3, bepristat 2a decreased the transendothelial migration of MCF-7 and
MDA-MB-231 cancer cells in a concentration-dependent manner (Figure 3I,J). In the case of transduced
MCF-7 cells, no inhibition was found in transmigration between shPDIA1-1 and shPDIA1-3 sublines
and the control shN group (Figure 3K), but the negative control MCF-7/shN displayed an inhibitory
effect. However, the MDA-MB-231/shPDIA1-3 subline showed non-statistically significant inhibition
of transmigration compared to MDA-MB-231/shN (Figure 3L).
2.10. Effects of Exogenous PDIA1 and PDIA3 Proteins on Adhesion of Cancer Cells to Fibronectin and Collagen
Type I and the Endothelium
The exogenous PDIA1 protein increased the adhesion of MCF-7 and MDA-MB-231 cell lines
to collagen and the hLMVEC monolayer (Figure 4A,C,G,I, respectively). However, the adhesion to
fibronectin was not affected (Figure 4B,H). Moreover, MCF-7 and MDA-MB-231 cell adhesion to various
substrates was not affected by exogenous PDIA3 (Figure 4D–F,J–L, respectively).
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Figure 4. Effects of exogenous PDIA1 and PDIA3 on adhesive interaction b tween breast cancer
cells and different substrates. Effect of exogenous proteins PDIA1 and PDIA3 on adhesion of MCF-7
(A–F) and MDA-MB-231 (G–L) cells to collagen type I, fibronectin and lung microvascular hLMVEC
cells, resp ctively. Data represent mean ± SD of three indep d nt xperiments. S atistical analysis
was performed using one-way ANOVA followed by Dunnett’s mu tiple compari on test (* p = 0.05,
** p = 0.01, *** p = 0.001).
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2.11. Effects of Thiol Blockers on Adhesion of Cancer Cells to Fibronectin and Collagen Type I
The cell-impermeable irreversible blocker of thiols and inhibitor of disulphide exchange agent
pCMBS blocked both MCF-7 and MDA-MB-231 cell adhesion to collagen I and fibronectin in a
concentration-dependent manner. Nearly complete inhibition of adhesion was observed at 500 µM
pCMBS (Figure 5A–D).Cancers 2020, 12, x 10 of 22 
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Figure 5. Effects of thiol blocker, pCMBS on adhesion of cancer cells to fibronectin and collagen type I.
Effect of inhibiting ecto-sulfhydryls by p-chloromercuribenzene sulphonate (pCMBS) on adhesion of
MCF-7 (A,B) and MDA-MB-231 (C,D) cells to collagen type I and fibronectin. Data represent mean
± SD of three independent experiments. Statistical analysis was performed using one-way ANOVA
followed by Dunnett’s multiple comparisons test (* p = 0.05, ** p = 0.01, *** p = 0.001).
2.12. Effect of PDIA1 Inhibition on ICAM-1 Expression
To verify whether bepristat 2a interfered with endothelial ICAM-1 expression, causing a decrease
in cancer cell adhesion and transendothelial migration, hLMVECs were pre-treated with 10 ng/mL
hIL-1β for 6 h, followed by treatment with bepristat 2a at various concentrations (1–50 µM) for 24 h.
Bepristat 2a caused no changes in ICAM-1 expression (Supplementary Figure S6).
2.13. Effect of PDIA1 Inhibition on Mitochondrial Respiration
To exclude the observed effects of bepristat 2a on cancer cell adhesion and transendothelial
migration being related to bioenergetic effect of this compound, mitocho drial respiration and
glycolysis were analysed. In hLMVECs, bepristat 2a induced no changes in mitochondrial respiration
(OCR) at concentrations of 1, 5, 10 or 30 µM, but slight, nonsignific t inhibitory effect of beprist t 2a
on mitochondrial espiration was visible at a concentratio of 50 µM (Supplementary Figure S7). In
MCF-7 and MDA-MB-231 cells, incubation wi h bepristat 2a for 24 h had no effect o mitochondrial
respiration, and only a slight, nonsignific nt decrease in OCR value was see after 50 µM bepristat 2 .
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2.14. Content of Integrins in MDA-MB-231, MCF-7 and hLMVEC Cell Lines
As shown in Table 4, β1 integrin was the most common and highly expressed integrin in all three
cell types. In hLMVECs, as well as β1 integrin, β3, β4, β5, α2, α3, α5, α6, αV integrins were detected.
Integrins α2, αV and α5 were also abundant but displayed lower expression levels compared with
integrin β1. In MCF-7 cells, the integrin α2 level was similar to β1 integrin. In MDA-MB-231, integrins
α2, α3, α6 and β4 were high, but their levels were lower than integrin β1.
Table 4. Content of integrins in hLMVEC, MCF-7 and MDA-MB-231 cell lines.
Integrin hLMVEC [Mean ± SD] MCF-7 [Mean ± SD] MDA-MB-231 [Mean ± SD]
β1 0.853 ± 0.133 0.250 ± 0.180 0.950 ± 0.499
β3 0.100 ± 0.000 not detected not detected
β4 0.050 ± 0.036 0.110 ± 0.000 0.347 ± 0.119
β5 0.050 ± 0.000 0.050 ± 0.000 0.050 ± 0.000
α2 0.430 ± 0.000 0.180 ± 0.000 0.407 ± 0.151
α3 0.157 ± 0.075 not detected 0.520 ± 0.115
α5 0.477 ± 0.064 not detected 0.080 ± 0.000
α6 0.183 ± 0.100 not detected 0.270 ± 0.200
αV 0.387 ± 0.050 0.040 ± 0.000 0.103 ± 0.060
Semi-quantitative data (emPAI) for integrins detected in lysates from human lung microvascular endothelial cells
(hLMVEC) and breast cancer MCF-7 and MDA-MB-231 cell lines. Data represent the means ± SD from three
consecutive passages. emPAI was calculated based on the number of observed peptides per proteins normalized by
the theoretical number of peptides subtracted from LC-MS/MS data using MascotTM (Matrix Sciences, London, UK).
3. Discussion
Adhesion of cancer cells to the endothelium and their subsequent transendothelial migration
represent important steps in metastasis, and PDIA1 expression has been suggested to promote
metastasis [10,31,32]. Here, we provide insight into the mechanisms involved and suggest that
PDIA1 regulates the adhesion and transendothelial migration of breast cancer cells via disulphide
re-arrangement of ecto-sulfhydryls, a mechanism previously described for integrin-mediated adhesion
of leukocytes and platelets [7,26–28]. We confirmed the role of PDIA1 in regulating the cell cycle and
apoptosis, which was translated into a noticeable anti-cancer effect in the colony formation assay
but not a substantial anti-proliferation effect in the classical assays. Altogether, our results showed
that, apart from the tumorigenic role of intracellular PDI in the ER [33], PDIA1 played a vital role in
regulating the adhesion of cancer cells and their transendothelial migration. The latter effects could be
attributed to the extracellular PDIA1 function of regulating integrin-mediated adhesion and subsequent
transendothelial migration of breast cancer cells, but not to the PDIA1-dependent regulation of ICAM-1
expression or changes in cellular bioenergetics in breast cancer or endothelial cells.
In the present work, to assess the functional role of PDIA1, we used two approaches: selective
inhibition of PDIA1 by bepristat 2a (IC50 2.1 µM, Table 3) and silencing of PDIA1 in breast cancer cells
by various silencing shPDIA1 hairpins. Although the major results were consistent in showing that the
inhibition of PDIA1 disrupted the cell cycle and diminished the transendothelial migration of breast
cancer cells, the effects of pharmacological inhibition by bepristat 2a were more substantial compared
with the silencing of PDIA1 in cancer cells. These results indicate that the silencing of cancer cells may
not necessarily provide a definite clarification as to the mechanisms involved. In fact, it might well be
that silencing PDIA1, a key cellular enzyme, in rapidly proliferating cells could induce adaptive changes
in the cancer cell proteome. That phenomenon is known in cancer cell biology; silencing approaches
might trigger an unwanted resistance response for the cells to cope with the hostile perturbation [34,35].
Moreover transduction procedure did not result in a 100% downregulation of PDIA1 (Figure S1 and
Table 2) so PDIA1 that stayed functional in cancer cells could be still partially active.
As a pharmacological tool to inhibit PDIA1, we chose bepristat 2a because most of the other
inhibitors of PDI identified in the last decade interact with the catalytic cysteines of PDI and are
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not selective towards PDI isoforms. However, bepristat 2a targets the substrate-binding domain of
PDI, making it selective against PDIA1 and not against other thiol isomerases [36], as also confirmed
here (Table 3). Previously, bepristats have been shown to impair platelet accumulation at sites of
vascular injury in an in vivo model of thrombus formation [36], a response dependent on PDIA1, as
confirmed in other studies [37]. Here, we have demonstrated for the first time, to our knowledge, that
bepristat 2a prevented the adhesion of MCF-7 and MDA-MB-231 cells to collagen, fibronectin and
endothelium, and impaired cancer cell transendothelial migration. A similar anti-adhesive effect was
shown by pCMBS, a membrane-impermeant thiol blocker. Moreover, we showed that human protein
PDIA1, but not PDIA3, increased cancer cell adhesion to the endothelial monolayer and collagen type
I. Altogether, our results provide evidence that PDIA1 is important in regulating cancer cell adhesion
to ECM proteins and endothelium by disulphide re-arrangement of ecto-sulfhydryls [26–28,37], in
addition to its anti-cancer effects, attributed to cycle–cycle regulation by intracellular PDI.
Previous studies exploring the biological significance of PDIs have shown that several PDIs such
as PDIA1, A3 and A6 play a significant role in cancer metastasis. Zhou et al. [25] reported that the
expression of PDIA1 was significantly upregulated in colon cancer tissues compared with normal colon
tissues and that its knockdown decreased cell proliferation and increased cell apoptosis in human
cancer HT29 cells. Xia et al. [24] also found that PDIA1 promoted hepatocellular carcinoma cell growth,
migration and invasion in vitro and tumour formation in vivo. Furthermore, the literature data indicate
that high expression of PDIA1 plays an important role in diffuse glioma progression, correlated with
high Ki-67 and more TP53 mutations [22]. Cell-surface PDIs have also been found to be associated with
cancer invasion and metastasis [38]. Our results are compatible with previous work on the importance
of intracellular PDIA1 in cancer progression. We have confirmed the involvement of PDIA1 in
cycle–cycle regulation and apoptosis as suggested previously and extended previous results [10,22,24]
by showing novel aspects of extracellular PDIA1-dependent regulation of tumourigenesis by affecting
cancer cell interactions with endothelium.
To the best of our knowledge, for the first time using a proteomic approach, we characterised a full
repertoire of PDIs in two human breast cancer cell lines: MCF-7 and MDA-MB-231. We demonstrated
that PDIA1 was the most abundant isoform of PDIs in these cell lines, which was consistent with
reports concerning the upregulation of PDIA1 in many cancer cell types [15]. Furthermore, PDIA1 was
also detected in extracellular media taken from MCF-7 and MDA-MB-231 cancer cells. Interestingly,
in primary lung microvascular endothelial cells, the level of PDIA1 was even higher than in breast
cancer cells. Although we did not detect extracellular PDIA1 in media dedicated for hLMVECs in
unstimulated cells, this cannot rule out PDIA1 being secreted by endothelial cells on injury or activation
and localised to the surfaces of these cells, because extracellular PDIA1 has been reported to contribute
to thrombus formation by catalysing the allosteric disulphide exchange in proteins such as tissue
factor [39,40]. Thus, it is tempting to suggest that PDIA1, the major isoform of PDIs in these cells,
released from cancer cells as well as hLMVECs, contributes to regulating cancer cell adhesion to
endothelium by supporting integrin-mediated adhesion, in a manner similar to that seen in interactions
between leukocytes [6,7] or platelets [41] and endothelium. Indeed, increasing evidence supports the
notion that integrin activation depends on thiol/disulphide exchanges [26,42–44]. It remains to be
established in further studies whether, apart from PDIA1, other PDIs including PDIA3, PDIA4 and
PDIA6 displaying relative high expression in breast cancer cells and endothelium are also involved in
regulating cancer cell interaction.
It has not been established here which type of integrin was involved in PDIA1-mediated cancer
cell adhesion, because this topic requires additional mechanistical studies. However, we showed that
in the presence of the membrane-impermeant thiol blocker pCMBS, cancer cell adhesion to collagen
type I (a specific counter-ligand for integrin α2β1) and fibronectin (mediated for integrin α5β1) was
effectively blocked. Another thiol blocker, DTNB, given at a non-toxic concentration (100 µM), also
effectively inhibited MDA-MB-231 and MCF-7 cell adhesion to ECM proteins. These findings suggest
that in PDIA1-mediated cancer cell adhesion, a major role can be ascribed to β1 integrin, which
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displayed the highest abundance of all integrins in breast cancer cells and pulmonary endothelial
cells. A similar experimental approach using pCMBS and DTNB was adopted in studies of the role of
thiols in platelet adhesion by Gofer-Dadosh [45] and Lahav et al. [46]. They showed that disulphide
exchange is a necessary step in platelet adhesion to collagen, mediated by α2β1 integrin, indicating a
specific involvement of surface PDIs in this process [27,28]. In our proteomic analysis, we observed
relatively high levels of β1 integrin in endothelial lung microvascular cells and breast cancer cells. α2
was also highly expressed in breast cancer cell lines, while α5 was abundant in pulmonary endothelial
cells. The role of β1 subunit–mediated adhesion seems most likely because in endothelial cells, β1 is
linked with proper localisation of VE-cadherin and thus is crucial to cell–cell junction integrity [47].
On the other hand, high levels of β1 integrin in MDA-MB-231 cells correspond to their highly invasive
phenotype and high efficiency of adhesion and migration [48], while MCF-7, as a non-invasive cell line,
exhibited much lower levels of β1-subunit in our proteomic analysis. Integrin α2 forms heterodimers
exclusively with β1 and has a widespread distribution in fibroblasts, endothelial cells, blood cells and
epithelial cells [49,50]. Together with integrin α5β1, but not other members of the β1 subfamily, it
plays a role in the maintenance of endothelial monolayer continuity in vitro [51]. In multiple types of
cancer, integrin α2β1 promotes metastasis. In a mouse model of melanoma, integrin α2 inhibition
resulted in diminished colon and breast cancer metastasis to the liver [52]. Monoclonal blocking
antibodies for α2β1 integrin, but not αVβ3, inhibited adhesion to collagen type I and hLMVECs
(unpublished data). Similar results were reported by Etoh et al. [53], who observed that blocking β1 and
α2 integrins by monoclonal antibodies caused inhibition of the migration of melanoma cells. Haidari et
al. [54] found that invasive MDA-MB-231 cells disrupted endothelial adherent junctions and promoted
transendothelial migration, activating α2β1 heterodimer and mediating tyrosine phosphorylation of
vascular endothelial cadherin. Accordingly, the role of β1 integrin in cancer cells (α2β1, α5β1) as well
as in endothelial cells (α2β1, αVβ1) could represent a target for PDIA1 action, but the involvement
of β3 integrin cannot be excluded [55,56]. Further studies are needed to set out which integrins
are involved in PDI-mediated regulation of breast cancer cell adhesion and transmigration. During
transendothelial migration, both tumour and endothelial cells undergo dynamic morphological and
cytoskeletal changes, and integrins β1 and β3, present on cancer cells and the endothelium, associated
with a variety of α chains, are active participants in the cell–cell interactions or cell-specific matrix
protein (e.g., laminin)–cell interactions [57–61]. Thus, modulating the activation of various integrins
on cancer and endothelial cells by a PDI-based approach seems to be more effective anti-metastatic
strategy then the inhibition of a single integrin. Confirmation of this thesis in future studies will shed
more light on that field.
Our previous results [29] clearly show that the suppression of cellular metabolism results in the
inhibition of adhesion and transendothelial migration of cancer cells. In the current study, we found
that bepristat 2a did not change mitochondrial respiration or glycolysis in cancer cells or endothelial
hLMVECs. Among several known adhesion molecules, ICAM-1 is important in interactions between
cancer and endothelial cells. We have previously established [29] that the adhesion of MDA-MB-231
cells to hLMVECs was significantly inhibited after blocking ICAM-1, but not VCAM-1 or E-selectin.
However, in the present study, we found that inhibition of PDIA1 did not impact ICAM-1 expression.
Altogether, these results excluded the existence of mechanisms of bepristat 2a activity comprising the
effects on energy metabolism or ICAM-1. This, in turn, supports that adhesion and transendothelial
migration of breast cancer cells is PDIA1 mediated. There are limitations of our study, including no
clear-cut explanation of dissimilar effects of PDIA1 silencing and PDIA1 pharmacological inhibition,
and lack of identification of a specific integrin involved. However, despite these shortcomings
pharmacological evidence clearly demonstrates the regulatory role of PDIA1 and disulphide exchange
in cancer cells adhesion and transendothelial migration.
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4. Materials and Methods
4.1. Cell Lines and Cell Culture
Human lung microvascular endothelial cell line (hLMVECs) was obtained from Cell Applications
(San Diego, CA, USA). Human breast adenocarcinoma MCF-7 cell line was purchased from the
European Collection of Authenticated Cell Cultures (ECACC, Salisbury, UK). MDA-MB-231 breast
cancer cell line was commercially obtained from the American Type Culture Collection (ATCC, Rockville,
Maryland, MD, USA). Lenti-X™ 293 T cell line (subclone of the transformed human embryonic kidney
cell line; HEK 293) was purchased from Clontech (Clontech Laboratories, Inc., Takara Bio USA, Inc.,
Mountain View, CA, USA) and was used for lentiviral vector production. hLMVECs were maintained
in microvascular endothelial cell growth medium (MECGM; Cell Applications, San Diego, CA, USA).
MDA-MB-231 cells were cultured in RPMI 1640 (Hirszfeld Institute of Immunology and Experimental
Therapy, Polish Academy of Sciences; HIIET PAS), supplemented with 2 mM L-glutamine and 10%
(v/v) FBS (both from Sigma-Aldrich, Steinheim, Germany). MCF-7 cells were cultured in Eagle medium
(HIIET PAS, Wroclaw, Poland), supplemented with 2 mM L-glutamine, 1% MEM non-essential amino
acid solution, 0.8 mg/L of human insulin solution (all from Sigma-Aldrich, Steinheim, Germany), and
10% (v/v) FBS (Thermo Scientific, Waltham, MA, USA). Both culture media, RPMI 1640 and Eagle
medium, contained antibiotics: 100 U/mL penicillin (Sigma-Aldrich, Steinheim, Germany), 100 µg/mL
streptomycin (Polfa Tarchomin, Warsaw, Poland) and 0.25 µg/mL amphotericin B (Sigma-Aldrich,
Steinheim, Germany). The Lenti-X™ 293 T cells were cultured in high-glucose Dulbecco’s Modified
Eagle Medium (Gibco, Scotland, UK), supplemented with 10% (v/v) FBS (HyClone, GE Healthcare,
Little Chalfont, UK) and 1 mM sodium pyruvate (Sigma-Aldrich, Steinheim, Germany). Cells were
maintained in an incubator at 5% CO2 in air and 37 ◦C. Regularly, cells were used for two to nine
passages after thawing. All cell lines were regularly tested for Mycoplasma (Lonza, Basel, Switzerland)
contamination before cryopreservation and every 3 months.
4.2. Proteomic Studies
hLMVECs, MDA-MB-231 and MCF-7 wild type breast cancer cell lines, and their sublines (shN,
shPDIA1-1 and shPDIA1-3) in three to five consecutive passages were seeded in equal amounts, grown
until 90–95% confluent, detached using Accutase solution (Sigma-Aldrich, Steinheim, Germany) and
washed twice with Dulbecco’s Phosphate-Buffered Saline (DPBS; Gibco, UK; 200 g, 5 min, room
temperature [RT]). The material was frozen at −80 ◦C until analysis. The cell lysate was prepared
for proteomic analysis according to Sitek et al. [62] with slight modifications. Briefly, 10 µg of
proteins were reduced, alkylated and digested with trypsin. The resulting peptides were subjected to
LC-MS/MS analysis (Mass Spectrometry Laboratory at the Institute of Biochemistry and Biophysics,
Polish Academy of Sciences, Warsaw, Poland) [63]. The acquired MS/MS data were pre-processed with
Mascot Distiller software (Matrix Science, London, UK), and a search was performed with the Mascot
search engine against the human proteins. For the detection and semi quantitation of PDI isoforms
and integrin isoforms, the exponentially modified protein abundance index (emPAI) calculation was
performed [64,65]. The detailed procedures for proteomic studies are described in the Supplementary
Materials and Methods.
4.3. Knockdown of PDIA1 in Human Breast Adenocarcinoma MDA-MB-231 and MCF-7
The third-generation lentiviral system consisting of pMDLg/pRRE, pRSV-Rev, pMD2.G (the
plasmids were a gift from Didier Trono; Addgene plasmid #12251, 12253, 12259) and expression plasmids
pGLV-H1-GFP-Puro (EZBiolab Inc., Carmel, IN, USA) were used to establish new MDA-MB-231 and
MCF-7 cell lines with silenced expression of PDIA1. The expression plasmids encoded three different
short hairpin RNA (shRNA) sequences designed for PDIA1 (shPDIA1 1–3). The control vector (used as
a negative control) encoded a negative shRNA sequence (shN). The map of the expression plasmid and
sequences of shRNA cloned to the plasmid is presented in Figure 6. Lentiviral vectors were produced
Cancers 2020, 12, 2850 15 of 22
using the Lenti-X™ 293 T cell line according to the protocol described by Rossowska et al. [66] and
applied to human MDA-MB-231 and MCF-7 cell line transduction.Cancers 2020, 12, x 15 of 22 
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Figure 6. The scheme of lentiviral vector used for silencing of PDIA1 expression and sequences of short
hairpin RNAs (shRNAs) cloned to the plasmid.
After transduction, the cell sublines MDA-MB-231/shPDIA1-1, MDA-MB-231/shPDIA1-2,
MDA-MB-231/shPDIA1-3, MDA-MB-231/shN, MCF-7/shPDIA1-1, MCF-7/shPDIA1-2,
MCF-7/shPDIA1-3 and MCF-7/shN were selected by culturing them in the growth medium
for MDA-MB-231 or MCF-7 cell line supplemented with 10 µg/mL puromycin (Gibco, Scotland, UK) to
obtain stable cell lines. The expression of PDIA1 in genetically modified cells was evaluated relative to
wild type MDA-MB-231 and MCF-7 cell lines.
4.4. Real-Time PCR and Western Blot
PDIA1 expression in the obtained cell sublines was analysed using real-time PCR and Western
blot assays. The detailed procedures for these assays are described in the Supplementary Materials
and Methods.
4.5. Measurements of Bepristat 2a Effect on Insulin Reduction Catalyzed by PDIA1 and Other PDIs
The protein disulfide isomerase activity was measured as an increase in disulfide bonds reduction
in human insulin in the presence of DTT causing aggregation of its β-chain, a process that can be
followed by turbidimetry. Briefly, the assay mixture for 96-well plates was prepared by dissolving
in 0.1 mM phosphate buffer (pH 7.6 for activity testing of PDIA1, PDIA3, PDIA4 or PDIA6 and pH
8.0 for PDIA17), 6 µg/mL (96 nM) of PDIA1 (recombinant protein MBS9422429, human, full length,
18-508aa His-tag, E.coli; (MyBioSource, San Diego, CA, USA), PDIA3 (recombinant protein MBS203583,
25-505aa, human, His-tag, E.coli, MyBioSource), PDIA4, (recombinant protein MBS2902080, 21-645aa,
human, His-tag, E.coli, MyBioSource), PDIA6 (recombinant protein MBS144267, 20-440aa, human,
His tag, E.coli, MyBioSource) or PDIA17 (recombinant protein ab64013, human, full length, E. coli,
(Abcam, Cambridge, UK), 2 mM EDTA and 0.08 mM DTT (D9779 Sigma-Aldrich, Steinheim, Germany).
Stock solutions of bepristat 2a were freshly prepared in DMSO and subsequently diluted to keep the
final DMSO concentration in assay mixture below 1%. Calculated amounts of compounds solutions
were added into test wells and the reaction was started by addition of insulin (insulin 91077C, human
recombinant; Sigma-Aldrich, Steinheim, Germany) and 0.08 mM of DTT. The final concentration of
insulin and DTT in assay mixture was 0.15 and 0.16 mM, respectively. The reaction rate was monitored
at 650 nm on a Microplate Reader Infinite M1000 PRO for 60 min at 37 ◦C. Turbidity values for the wells
containing only the PDI isoform tested (background values) was subtracted from the turbidity values
of the wells containing PDI isoform tested + bepristat 2a. The inhibition of PDI isoform’s catalytic
activity in the presence of bepristat 2a was calculated by the following formula: enzyme inhibition
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(%) = [1 − (OD[bepristat + PDI + DTT] − OD[DTT])/(OD[PDI + DTT] − OD[DTT])] × 100%, where OD
means optical density.
4.6. SRB Assay
The proliferation rate of the cells with silenced expression of PDIA1 was measured using SRB
assay (see Supplementary Materials and Methods for more details).
4.7. MTS Assay
The effect of bepristat 2a on endothelial and breast cancer cell viability was determined by MTS
assay (see Supplementary Materials and Methods for more details).
4.8. Caspase 3/7 Activity
Measurements of the caspase 3/7 activity were performed with fluorogenic assay as described in
the Supplementary Materials and Methods.
4.9. Cell Cycle Analysis
Flow cytometry was used to assess the effect of PDIA1 inhibition on the cell cycle progression
of MDA-MB-231 and MCF-7 cells. This procedure is described in the Supplementary Materials
and Methods.
4.10. Long-Term Colony Formation Assay
The long-term colony formation assay was performed as previously described by Pawlak [67].
MDA-MB-231 and MCF-7 cell lines and their sublines with PDIA1 silenced (shN, shPDIA1-1 and
shPDIA1-3) were seeded on 6-well plates in triplicate (Corning, Kennebunk, ME, USA) for 9-day
colony formation assay in the appropriate culture medium, at a density of 1 × 103 cells/well and 5 ×
102 cells/well for MDA-MB-231 and MCF-7, respectively, on the day of subculturing. To confirm a
long-lasting reduction in clonogenic potential by bepristat 2a hydrochloride (Sigma-Aldrich, Steinheim,
Germany), 24 h before adding the tested compound, MDA-MB-231 and MCF-7 cells were seeded on
six-well plates (Corning, Kennebunk, ME, USA) at a density of 0.5 × 106 cells/well. The cells were
treated with bepristat 2a at concentrations of 10, 30 and 50 µM and collected after 24 h of incubation.
The viable cells were counted and seeded in triplicate at the densities described on six-well plates.
After 9 days, the colonies were fixed and stained with 1% crystal violet/methanol (Sigma-Aldrich),
documented with a Sony Alpha 300 camera (Sony, Tokyo, Japan) and counted manually using ImageJ
1.47 software (National Institutes of Health, Bethesda, MD, USA). The colony number was calculated.
4.11. Electric Cell-Substrate Impedance-Sensing Assays
To measure the migratory potential of cancer cells with silenced PDIA1 or the impact of bepristat 2a
on the migration rate of hLMVEC, MDA-MB-231 and MCF-7 cells, real-time quantitative wound-healing
assays were performed and the 96W1E+ ECIS arrays (Applied BioPhysics, Troy, NY, USA) were used.
Before the cell seeding procedure, the 96W1E+ plate was pre-treated for 10 min with 10 mM L-cysteine
(Sigma-Aldrich, Steinheim, Germany) at RT and washed twice by ultrapure water. After washing, 200
µL of MECGM (for hLMVECs), RPMI1640 (for MDA-MB-231) or Eagle medium (for MCF-7) were
added to each well to check resistance (Ω), capacitance (µF) and impedance (Ω) basal values. Then,
the cells were added (hLMVEC and MDA-MB-231 cell lines were seeded at a density of 3 × 104 per
well, MCF-7 cell lines at a density of 6 × 104 cells per well) with MECGM, RPMI1640 or Eagle medium,
respectively, in a final volume of 300 µL. Resistance, capacitance and impedance values were recorded
at frequencies from 250 Hz to 64 kHz (250, 500, 1000, 2000, 4000, 8000, 16,000, 32,000 and 64,000 Hz)
using the multiple frequency time mode. The cell-free wells served as a negative control to provide
the baseline changes in impedance for all experiments. Wounding was performed by applying an
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alternating current of 1600 µA, 64 kHz for 30 s, killing the cells on the surface of the electrode, which
resulted in an abrupt drop in impedance to values like those of a cell-free electrode. The dead cells
were washed away and fresh medium was added (for sublines with PDIA1 silenced) or medium
containing bepristat 2a at various concentrations (1, 10, 30 or 50 µM). The healing process was measured
continuously as cells migrated onto the electrode. The area under the curve (AUC) was quantified
and normalized to untreated control or negative control (shN). The experiment was performed in a
humidified 5% CO2 incubator at 37 ◦C and was repeated three times in seven technical replicates.
4.12. Adhesion Assay
4.12.1. Cancer Cell Adhesion to Lung Microvascular Endothelial Cells
The hLMVECs were transferred into 96-well plates (seeding density 2.5 × 104 cells/well) and
left to grow to confluence for 48–72 h. Endothelial cells were stimulated with 10 ng/mL hIL-1β (Cell
Signalling Technology, Leiden, The Netherlands) for 6 h. To determine the contribution of PDIA1 in
cancer cell adhesion to the endothelial monolayer, pharmacological inhibitor, bepristat 2a or human
PDIA1 protein and MDA-MB-231 and MCF-7 cell lines with silencing of PDIA1 (shN, shPDIA1-1
and shPDIA1-3) were used. Before use for the cell adhesion assay, MDA-MB-231 or MCF-7 cells
were stained with Calcein-AM (BD Pharmingen, San Jose, CA, USA) according to the manufacturer’s
instruction. Then, cancer cells were left to adhere to the endothelial layer with or without bepristat
2a at various concentrations (1, 10, 30 or 50 µM) for 30 min at 37 ◦C. Non-adherent cells were gently
washed twice with DPBS.
In all assays, the attached cells were counted in six to nine randomly selected visual fields for each
well. Pictures were taken using the CQ1 image cytometer (Yokogawa, Tokyo, Japan). Experiments were
conducted three times in five to six technical replicates. The images were analysed using Columbus v.
2.4.2 software (Perkin Elmer, Waltham, MA, USA). The mean inhibition of adhesion for visual fields was
calculated by using the equation: % of control = [number of adhered cells in treated samples/number
of adhered cells in control group] × 100%.
4.12.2. Cancer Cell Adhesion to Fibronectin or Collagen Type I
MDA-MB-231 and MCF-7 cell lines and their sublines (shN, shPDIA1-1 and shPDIA1-3) were
seeded at a density of 5 × 105 cells/well in the appropriate culture medium with 10% (v/v) FBS in 96-well
plates (Corning, Kennebunk, ME, USA). The next day, the culture medium was changed to medium
with 5% (v/v) FBS alone (all cell lines) or along with 10, 30 and 50 µM bepristat 2a hydrochloride
(only wild type MDA-MB-231 and MCF-7 cell lines). On the same day, 96-well plates (Thermo Fisher
Scientific, Waltham, MA, USA) were coated with collagen type I or fibronectin, both at a concentration
of 10 µg/mL (both from Sigma-Aldrich, Steinheim, Germany), and incubated at 4 ◦C overnight. After
24 h, the plates were blocked with 1% BSA (Sigma-Aldrich, Steinheim, Germany) in TSM buffer (20
mM Tris-HCl pH 8.0, 150 nM NaCl, 1 mM CaCl2, 2 mM MgCl2; HIIET) for 30 min at 37 ◦C. On the
same day, cells were nonenzymatically detached, centrifuged, counted and suspended in TSM buffer.
Next, the 5 × 104 cells/well were seeded in the coated plates and incubated at 37 ◦C for 1 h. After
incubation, the cells were stained with 0.2% (w/v) crystal violet dissolved in methanol. The plate was
incubated at 4 ◦C for 30 min. The absorbance was measured at 570 nm using a Synergy H4 reader and
GEN5 software. The experiment was repeated at least three times.
The effect of the sulfhydryl blocker on cancer cell adhesion to fibronectin and collagen type
I was measured using a membrane non-penetrating reagent, p-chloromercuribenzene sulphonate
(pCMBS; Toronto Research Chemicals, Toronto, Ontario, Canada). Human PDIA1 protein (Pure
Biologics, Wroclaw, Poland) was used to examine the effect of exogenous PDIA1 on both cancer cells’
adhesion to extracellular matrix (ECM) proteins. Briefly, after overnight coating with collagen type I or
fibronectin, the 96-well plates were blocked with 1% BSA in PBS for 30 min at 37 ◦C. Before adding
MCF-7 and MDA-MB-231 cells into the cell adhesion assay, cancer cells were stained with Calcein-AM
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(BD Pharmingen, San Jose, CA, USA), and pCMBS was added 15 min before introduction of MCF-7
and MDA-MB-231 to the adhesive surfaces. Then, cancer cells were left to adhere to collagen I and
fibronectin for 30 min at 37 ◦C. Non-adherent cells were gently washed twice with DPBS, and attached
cells were counted in six randomly selected visual fields for each well using the CQ1 image cytometer.
The experiment was conducted three times in six technical replicates.
4.13. Transendothelial Migration Assay
Cell migration was assayed in 24-well, 6.5-mm internal diameter Transwell plates (8.0-µm pore
size; BD Pharmingen, San Jose, CA, USA). hLMVECs (seeding density 5 × 104 cells/insert) were first
cultured for 72 h on the upper side of the filter with complete medium. After confluent monolayer
formation, the hLMVECs were pre-treated with 10 ng/mL hIL-1β for 6 h. Then, MDA-MB-231 or
MCF-7 cells (wild type or their sublines with silenced PDIA1, each 5 × 104 per well) were placed into
upper chambers in the presence or absence of bepristat 2a at various concentrations (1, 10, 30 or 50 µM).
Lower chambers were filled with EBM-2 serum-free medium (Lonza, Basel, Switzerland) containing
stromal cell-derived factor 1α (SDF-1, 100 ng/mL; Sigma-Aldrich, Steinheim, Germany). After 24 h of
co-culture, hLMVEC monolayers and non-migrating cancer cells on the upper surface of the membrane
were removed, and migrated cancer cells on the undersides of the Transwell membranes were detached
and stained by Calcein-AM−Accutase solution for 60 min. The cell number was determined by
measuring the fluorescence using a plate reader. The experiments were performed three times with
three technical replicates.
4.14. Expression of ICAM-1
Immunostaining was performed to verify whether bepristat 2a interferes with surface ICAM-1
expression in hLMVECs (see Supplementary Materials and Methods for detailed method description).
4.15. Analysis of Cellular Bioenergetics by Extracellular Flux Technology
To determine whether the effects of bepristat 2a on the interactions between MCF-7 and
MDA-MB-231 and hLMVECs were correlated with their effects on the oxygen consumption rate
(OCR) and extracellular acidification rate (ECAR), a Seahorse XF technique was used (a detailed
procedure for this method is provided in the Supplementary Materials and Methods).
4.16. Statistical Analysis
All results are presented as the mean value ± standard deviation (SD). Statistical analysis was
performed using GrapPad Prism 7 (San Diego, CA, USA). The assumptions of analysis of variance
(ANOVA) were checked using the Shapiro–Wilk normality test and the Brown–Forsythe test. If the
assumptions of the parametric test were fulfilled, a one-way ANOVA test followed by Dunnett’s
multiple comparisons test was run. If they were not met, the nonparametric Kruskal–Wallis test was
performed, followed by Dunn’s multiple comparisons test. Specific tests used for data analysis are listed
in the figure legends. Differences with p-values lower than 0.05 were considered statistically significant.
5. Conclusions
The current study is the first to demonstrate that extracellular PDIA1 regulates breast cancer
interactions with lung microvascular endothelial cells during metastasis. Described mechanism
involves disulphide exchange and most likely activation of integrin-mediated cancer cell adhesion and
transmigration. Whether other isoforms of PDIs also regulate this process similarly to multiple PDIs
involved in activating platelet integrins [40,46,68,69] remains to be established. Finally, our results
suggest that the inhibition of extracellular PDIA1 or other PDIs represents an interesting target for
anti-metastatic treatment that warrants further exploration. Changes in endothelial function have an
impact on the development and progression of almost all diseases. Thus, expanding the knowledge of
Cancers 2020, 12, 2850 19 of 22
endothelial repertoire of PDIs and understanding specific molecular mechanisms used by cancer cells
in dynamic interactions with endothelial cells will help to identify promising molecular targets for
anticancer therapy.
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